277 related articles for article (PubMed ID: 30653479)
1. IV aprepitant (Cinvanti) for chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2018 Dec; 60(1561):e200-e201. PubMed ID: 30653479
[No Abstract] [Full Text] [Related]
2. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
3. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
Navari RM
Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
[No Abstract] [Full Text] [Related]
4. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
5. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
Rapoport B; Smit T
Expert Opin Drug Saf; 2017 Jun; 16(6):697-710. PubMed ID: 28460548
[TBL] [Abstract][Full Text] [Related]
6. Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant.
Rapoport BL; Jordan K; Weinstein C
Future Oncol; 2018 Jan; 14(1):77-92. PubMed ID: 29130344
[TBL] [Abstract][Full Text] [Related]
7. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
8. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis.
Navari RM
Future Oncol; 2019 Jan; 15(3):241-255. PubMed ID: 30304952
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
[TBL] [Abstract][Full Text] [Related]
10. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
[TBL] [Abstract][Full Text] [Related]
11. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK
Bošnjak SM; Gralla RJ; Schwartzberg L
Support Care Cancer; 2017 May; 25(5):1661-1671. PubMed ID: 28108820
[TBL] [Abstract][Full Text] [Related]
12. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract][Full Text] [Related]
13. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
15. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy.
Schwartzberg LS; McLaughlin T; Geller RB; Gabrail NY; Marks SM
J Comp Eff Res; 2018 Dec; 7(12):1161-1170. PubMed ID: 30304955
[TBL] [Abstract][Full Text] [Related]
17. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
18. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
20. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
